Research Article Cites HemogloBind™ in Parkinson’s Disease Study

In this study, Parkinson’s disease progression is investigated through the accumulation and aggregation of the lipid-binding SNARE complex component alpha-synuclein (SNCA) which underlies vulnerability and defines its stages. The authors studied blood samples from a new large pedigree with SNCA gene duplication (PARK4 mutation), to identify effects of SNCA gain-of-function as potential disease biomarkers. The article states “For protein extraction from the EDTA tubes, 300 μl blood were lysed with equal amount of 1% SDS-RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Igepal CA-630 (Sigma), 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF and one tablet Complete Protease Inhibitor Cocktail (Roche)] and sonicated for 10 sec. The blood lysates were rotated at 4 °C for 30 min and centrifuged at 4 °C for 30 min. The supernatants were depleted in hemoglobin content using a commercial kit (HemogloBind, Biotech) following the manufacturer’s instructions”. After hemoglobin depletion, immunoblot analysis identified that PARK4 blood showed upregulation of alpha-synuclein monomer, with no high molecular weight aggregates.


Research Article Cites HemoVoid™ in Red Blood Cell Proteome Study

In brief, using proteomics-based evaluation of red blood cells (RBC), the authors identified differentially abundant proteins associated with Obstructive Sleep Apnea Syndrome (OSA). Proteome variations between various time points were assessed. The article states “RBC cytoplasmic fraction depleted of hemoglobin, using Hemovoid™ system, were analyzed by two-dimensional fluorescence difference gel electrophoresis (2D-DIGE), the 2D image software-based analyzed and relevant differentially abundant proteins identified by mass spectrometry (MS)”. The authors conclude that 31protein spots were differentially abundant, corresponding to 21 unique proteins possibly due to the existence of post-translational modifications.


Patent Cites HemogloBind™ in Complement Mediation

The invention describes synthetic peptide compounds and uses for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The patent states “Due to large amounts of hemolysis in the latter time points and the associated optical interference in bilirubin analysis, all the samples were pre-treated with HemogloBind™ (Biotech, N.J.) prior to analysis with the Bilirubin Assay Kit”.


Research Article Cites HemogloBind™ in Cancer Derived Exosome Study

This study considers that therapeutic strategies targeting cancer-derived extracellular vesicles (EVs) hold great promise because of the possibility they reposition microenvironments to accommodate metastasis. The researchers report on a novel strategy of therapeutic antibody treatment to target cancer-derived EVs and inhibit the metastasis of breast cancer in a mouse model. The article states “Hemoglobin was accumulated with HemogloBind beads (Biotech support group, Monmouth Junction NJ, USA) followed by 0.22 μm filtration. Then, the EVs in the sera were concentrated by ultracentrifugation…”. The authors conclude that therapeutic antibody administration effectively suppresses EV-triggered metastasis and that the elimination of cancer-exosome derived EVs could be a novel strategy for therapy.


Research Article Cites Cleanascite™ for Mass Spectrometric Proteome Analysis of Human Bile Fluid

In brief, the article’s authors report methods to overcome the biological variability of analyzing a high number of bile samples. They advance that easy sample preparation protocols are demanded representing a compromise between proteome coverage and simplicity in this study. For this, they evaluated the performance of simple workflows allowing for "one sample, one shot" experiments to identify biomarker candidates for various diseases of the hepatobiliary system. In detail, sixteen different protocols with modifications at the stages of desalting, delipidation, deglycosylation and tryptic digestion were examined. The article states “For delipidation, the Cleanascite™ Lipid Removal Reagent and Clarification Kit (BSG, NJ 08852, USA) was used following manufacturer's instructions.”. The authors concluded that delipidation yielded a considerable number of complementary protein identifications and that Cleanascite™ treatment was indispensable for in-solution digestion methods.


Proteomics Research Article Cites HemogloBind™ in Profiling Lung Injury

The authors consider pulmonary complications due to infection and idiopathic pneumonia syndrome (IPS) in hematopoietic stem cell transplant (HSCT) recipients. For this, a proteomic characterization of global bronchoalveolar lavage fluid (BALF) was studied to identify proteins and pathways that differentiate IPS from infectious lung injury after HSCT. Because the BALF samples appeared tinged with blood, the authors tested HemogloBind™ to determine whether the removal of hemoglobin (in addition to high-abundance proteins) would improve the depth of coverage. The article states “Hemoglobin removal improved protein identification to 845 proteins at 1% global FDR compared with 496 proteins with high-abundance protein depletion alone”. The authors conclude that the protein expression differences provide insights into mechanisms activated in lung injury and suggest potential therapeutic targets to augment lung repair.